FDA Finds Long-Term Treatment with Clopidogrel Does Not Affect Risk of Death

​A recent U.S. Food and Drug Administration (FDA) evaluation of Plavix (clopidogrel) concluded that long-term use of the drug does not increase or decrease the overall risk of death in patients with, or at risk of, heart disease. According to a November 6, 2015, FDA drug safety communication, FDA's evaluation also found no evidence suggesting that the drug increases the risk of cancer or mortality related to cancer.